About: Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019
Creator	Hong, Hyo-Lim Jung, Young Kim, Bs, Eun-Jin Chang-Ho Jeon, \| Chi, \| Choe, Jung-Yoon Correspondence, Seong-Kyu Kim, Ji-Won Kim, Seong-Kyu Kwon, Hyun
Source	Medline; PMC
abstract	Serologic assays have been developed to detect infection with coronavirus disease 2019 (COVID‐19). This study was conducted to evaluate the diagnostic performance of an immunochromatography‐based assay of human serum for COVID‐19. The present study enrolled 149 subjects who had been tested by real‐time reverse transcription‐polymerase chain reaction (RT‐PCR) for COVID‐19 and were classified into two groups: 70 who were positive for COVID‐19 and 79 who were negative for COVID‐19 based on RT‐PCR. An immunochromatography‐based COVID‐19 immunoglobulin G (IgG)/immunoglobulin M (IgM) rapid test on the sera of the study population was applied to measure the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and receiver operating characteristic (ROC) curve compared to RT‐PCR, with a 95% confidence interval (CI). IgM or IgG antibodies were detected in 65 subjects (92.9%) classified as positive for COVID‐19 and in three subjects (3.8%) classified as negative for COVID‐19. The sensitivity and specificity percentages for IgM or IgG antibodies were 92.9% (95% CI: 84.1‐97.6) and 96.2% (95% CI: 89.3‐99.2), respectively, with 95.6% PPV and 93.8% NPV. The PPV rapidly improved with increasing disease prevalence from 19.8% to 96.1% in the presence of either IgM or IgG, while the NPV remained high with a change from 99.9% to 93.1%. The area under the ROC curve was 0.945 (95% CI: 0.903‐0.988) for subjects with either IgM or IgG positivity. In conclusion, the immunochromatography‐based COVID‐19 IgG/IgM rapid test is a useful and practical diagnostic assay for detection of COVID‐19, especially in the presence of IgM or IgG antibodies.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1002/jmv.26060
bibo:pmid	32458479
has license	no-cc
sha1sum (hex)	7fafc7d8eae5dc2162c27ffdb640047f2fe73ea7
schema:url	https://doi.org/10.1002/jmv.26060
resource representing a document's title	Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019
has PubMed Central identifier	PMC7283626
has PubMed identifier	32458479
schema:publication	J Med Virol
resource representing a document's body	covid:7fafc7d8eae5dc2162c27ffdb640047f2fe73ea7#body_text
is schema:about of	named entity 'positive' named entity 'COVID-19' named entity 'Diagnostic' named entity 'performance' named entity 'PRESENT' named entity 'COVID-19' named entity 'BASED' named entity 'DETECTION' named entity 'PCR' named entity 'HOW' named entity 'SEROLOGIC' named entity 'negative' named entity 'cite' named entity 'assays' named entity 'Diagnostic' named entity 'based' named entity 'How' named entity 'IgG' named entity 'RT-PCR' named entity 'assay' named entity 'antigens' named entity 'coronavirus disease 2019' named entity 'COVID-19' named entity 'disease prevalence' named entity 'IgG antibody' named entity 'diagnostic tools' named entity 'RT-PCR' named entity 'gene' named entity 'headache' named entity 'WHO' named entity 'COVID' named entity 'IgM' named entity '99.9%' named entity 'antibody' named entity 'RT-PCR' named entity 'SARSr-CoV' named entity 'COVID-19 infection' named entity 'microbial' named entity 'rapid test' named entity 'IgG antibodies' named entity 'COVID' named entity 'RT-PCR' named entity 'nucleic acid amplification test' named entity 'NPV' named entity 'RT-PCR' named entity 'IgG antibodies' named entity 'RT-PCR' named entity 'RT-PCR' named entity 'serum' named entity 'IgG' named entity 'antibodies' named entity 'cross-sectional' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'immunoglobulin' named entity 'IgM' named entity 'RT-PCR' named entity 'Norovirus' named entity 'study population' named entity 'NAAT' named entity 'coronavirus' named entity 'next-generation sequencing' named entity 'COVID-19' named entity 'titer' named entity 'assay' named entity 'laboratory equipment' named entity 'sensitivity, specificity' named entity 'study population' named entity 'mortality rate' named entity 'IgM' named entity '95% confidence interval'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software